Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.34 |
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6879610 | 1.00 | CLK4 (0.39) | CLK4ADRB2AOC3MKNK1MKNK2 | |
| SCHEMBL6879603 | 1.00 | CLK4 (0.39) | CLK4ADRB2AOC3MKNK1MKNK2 | |
| SCHEMBL6852193 | 0.78 | CLK4 (0.41) | CLK4ADRB2AOC3MKNK1MKNK2 | |
| SCHEMBL6852195 | 0.78 | CLK4 (0.41) | CLK4ADRB2AOC3MKNK1MKNK2 | |
| SCHEMBL6869730 | 0.75 | ADRB2 (0.43) | CLK4ADRB2AOC3MKNK1MKNK2 | |
| SCHEMBL6869726 | 0.75 | ADRB2 (0.43) | CLK4ADRB2AOC3MKNK1MKNK2 | |
| SCHEMBL6877431 | 0.75 | ADRB2 (0.43) | CLK4ADRB2AOC3MKNK1MKNK2 | |
| SCHEMBL28150019 | 0.74 | TDP1 (0.44) | CYP2A6CYP3A4KMT2AMEN1 | |
| SCHEMBL28072476 | 0.71 | CES2 (0.44) | CYP3A4 | |
| SCHEMBL6685962 | 0.71 | CLK4 (0.64) | CLK4ADRB2AOC3HDAC4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825170-B2 | ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | Q6ZSR9, ACSL6, RPS4Y1 | CLK4 3870/4885ADRB2 4390/4885AOC3 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.